Condensed Consolidated Interim Financial Statements as of September 30, 2016

Bayer Group
Consolidated Income Statements

 

 

Q3 2015

Q3 2016

 

9M 2015

9M 2016

 

 

€ million

€ million

 

€ million

€ million

2015 figures restated

1

EBIT = income after income taxes, plus income taxes, plus financial result

Net sales

 

11,004

11,262

 

34,800

34,949

Cost of goods sold

 

(4,940)

(4,828)

 

(15,643)

(14,900)

Gross profit

 

6,064

6,434

 

19,157

20,049

Selling expenses

 

(2,908)

(2,957)

 

(8,952)

(8,937)

Research and development expenses

 

(1,039)

(1,122)

 

(3,018)

(3,353)

General administration expenses

 

(508)

(587)

 

(1,526)

(1,571)

Other operating income

 

361

203

 

639

565

Other operating expenses

 

(398)

(176)

 

(980)

(500)

EBIT1

 

1,572

1,795

 

5,320

6,253

Equity-method loss

 

(4)

(6)

 

(4)

(17)

Financial income

 

32

34

 

129

113

Financial expenses

 

(308)

(302)

 

(966)

(999)

Financial result

 

(280)

(274)

 

(841)

(903)

Income before income taxes

 

1,292

1,521

 

4,479

5,350

Income taxes

 

(298)

(305)

 

(1,057)

(1,210)

Income from continuing operations after income taxes

 

994

1,216

 

3,422

4,140

Income from discontinued operations after income taxes

 

11

74

 

93

179

Income after income taxes

 

1,005

1,290

 

3,515

4,319

of which attributable to noncontrolling interest

 

6

103

 

18

241

of which attributable to Bayer AG stockholders (net income)

 

999

1,187

 

3,497

4,078

 

 

 

 

 

 

 

 

 

in €

in €

 

in €

in €

Earnings per share

 

 

 

 

 

 

From continuing operations

 

 

 

 

 

 

Basic

 

1.19

1.34

 

4.11

4.71

Diluted

 

1.19

1.34

 

4.11

4.71

From discontinued operations

 

 

 

 

 

 

Basic

 

0.02

0.09

 

0.12

0.22

Diluted

 

0.02

0.09

 

0.12

0.22

From continuing and discontinued operations

 

 

 

 

 

 

Basic

 

1.21

1.43

 

4.23

4.93

Diluted

 

1.21

1.43

 

4.23

4.93